Literature DB >> 27433584

Stearylamine-Containing Cationic Nanoemulsion as a Promising Carrier for Gene Delivery.

André L Silva, Henrique R Marcelino, Lourena M Verissimo, Ivonete B Araujo, Lucymara F Agnez-Lima, Eryvaldo S T do Egito.   

Abstract

The drawbacks related to the use of viral vectors in gene therapy have been stimulated the research in non-viral strategies such as cationic nanoemulsions. The aim of this work was to develop a stearylamine-containing nanoemulsion for gene therapy purpose. The formulation was chosen from a Pseudo-Ternary Phase Diagram and had its long-term stability assessed by Dynamic Light Scattering and Phase Analysis Light Scattering during 180 days at 4 degrees C, 25 degrees C and 40 degrees C. Besides, studies of sterilization and scale up of the product were conducted. It was demonstrated that the proposed system was stable up to 180 days when stored at 4 degrees C and could be sterilized by a 0.22 microm filter pore without changes on its characteristics. The scale up was possible by adjusting the volume to the sonication time. Because the nanoemulsion presented a droplet size smaller than 200 nm and a zeta potential higher than 30 mV, this system was able to correctly complex the plasmid model PIRES2-EGFP, as confirmed by the agarosis gel electrophoresis assay. The nanoemulsion toxicity evaluated over lung fetus human cells (MRC-5) was dose-dependent. However, it does not appear to be a limiting factor for further experiments aiming gene transfection. As a conclusion, stearylamine-containing cationic nanoemulsions can be used for gene therapy, since it presents suitable characteristics, stability and possibility of sterilization.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27433584     DOI: 10.1166/jnn.2016.11671

Source DB:  PubMed          Journal:  J Nanosci Nanotechnol        ISSN: 1533-4880


  2 in total

1.  Zein/Phospholipid Composite Nanoparticles for Successful Delivery of Gallic Acid into aHSCs: Influence of Size, Surface Charge, and Vitamin A Coupling.

Authors:  Shaimaa Ali Ali Radwan; Walaa H El-Maadawy; Carol Yousry; Aliaa Nabil ElMeshad; Raguia Aly Shoukri
Journal:  Int J Nanomedicine       Date:  2020-10-16

2.  Sphingomyelin-Based Nanosystems (SNs) for the Development of Anticancer miRNA Therapeutics.

Authors:  Surasa Nagachinta; Belen Lopez Bouzo; Abi Judit Vazquez-Rios; Rafael Lopez; Maria de la Fuente
Journal:  Pharmaceutics       Date:  2020-02-22       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.